Novo Nordisk (NYSE: NVO)
Novo Nordisk Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novo Nordisk Company Info
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
News & Analysis
3 Stocks That Could Be Monster Winners in 2025
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.
Is Novo Nordisk Stock a Buy?
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.
2 No-Brainer Dividend Growth Stocks to Buy Right Now
These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
The thrust of the company's long-term strategy is becoming clearer.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.